Please wait while the formulary information is being retrieved.
PULMOZYME (DORNASE ALFA)
- Respiratory cystic fibrosis
1 mg/mL solution for inhalation
- Inhale 2.5 mg by inhalation route once daily via nebulizer
Respiratory cystic fibrosis
- Inhale 2.5 mg by inhalation route once daily via nebulizer
- Inhale 2.5 mg by inhalation route 2 times per day via nebulizer
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Bronchiectasis
PULMOZYME (DORNASE ALFA)
- Respiratory cystic fibrosis
- None
- Chest pain
- Conjunctivitis
- Decrease in forced vital capacity
- Dyspnea
- Fever
- Hoarseness
- Laryngitis
- Pharyngitis
- Rhinitis
- Skin rash
- Sore throat
- Voice change
More Frequent
Severe
Less Severe
- None
- Dyspepsia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Dornase alfa
Limited safety data age < 5 years.
- 1 Day – 5 Years
- Limited safety data age < 5 years.
Dornase Alfa
- Severity Level:
2
- Additional Notes: Insuff human data; animal data sug no dev tox at doses > than 10 x mrhd
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Dornase Alfa
No data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | No data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Respiratory cystic fibrosis | |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| 0-9 | A-Z |
|---|---|
| E84.0 | Cystic fibrosis with pulmonary manifestations |
Formulary Reference Tool